Posted by Michael Wonder on 27 Jan 2021
NICE recommends Revlimid for newly diagnosed multiple myeloma patients
27 January 2021 - Bristol Myers Squibb’s Revlimid (lenalidomide) has received a recommendation from the UK’s NICE for newly diagnosed multiple myeloma patients.
In its Final Appraisal Document, NICE recommended Revlimid as a maintenance treatment after autologous stem cell transplant for newly diagnosed multiple myeloma in adults.
